Arrowhead Research Corp. (ARWR) Trading 3.1% Higher
Arrowhead Research Corp. (NASDAQ:ARWR) shares traded up 3.1% during trading on Friday . The company traded as high as $5.76 and last traded at $5.71, with a volume of 160,275 shares changing hands. The stock had previously closed at $5.54.
A number of research analysts recently commented on the stock. Vetr lowered shares of Arrowhead Research Corp. from a “buy” rating to a “hold” rating and set a $6.49 price target on the stock. in a research note on Tuesday, April 19th. Jefferies Group reiterated a “hold” rating and issued a $4.75 price target on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. Finally, Chardan Capital assumed coverage on shares of Arrowhead Research Corp. in a research note on Thursday, May 19th. They issued a “buy” rating and a $12.00 price target on the stock. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $10.27.
The stock’s 50 day moving average price is $5.76 and its 200-day moving average price is $5.05. The firm’s market capitalization is $348.37 million.
Arrowhead Research Corp. (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. On average, analysts expect that Arrowhead Research Corp. will post ($1.40) earnings per share for the current fiscal year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.